What We're Reading: Page 176
Industry reads hand-picked by our editors
Nov 16, 2020
-
FiercePharma
2020's Fiercest Women in Life Sciences
-
Pittsburgh Business Times
After nearly 60 years, Mylan makes way for Viatris
-
Endpoints News
Sanofi grapples with rejection of potential first-in-class orphan drug, faults third-party manufacturing
-
TCT MD
Fish Oil Tanks in STRENGTH, Making Waves For REDUCE-IT
Nov 13, 2020
-
The Wall Street Journal
How a Coronavirus Vaccine Maker’s Stock Went From Dud to Star
-
Bloomberg
J&J Taps UnitedHealth to Accelerate Vaccine Trial
-
STAT
An FDA adviser on why his panel didn't endorse Biogen's Alzheimer's drug
-
Endpoints News
Doubling down on Sanofi's French roots, Paul Hudson infuses €50M into Jeito Capital to boost homegrown biotechs
Nov 12, 2020
-
Wired
More Safety Data Would Be Nice, But We Need a Vaccine Now
-
The Wall Street Journal
Kodak Says Ex-Executives Sold Stock Options They Didn’t Own
-
Science
Russia's claim of a successful COVID-19 vaccine doesn’t pass the 'smell test,' critics say
-
NPR
Novavax Releases Federal Contract To Develop COVID-19 Vaccine
Nov 11, 2020
Nov 10, 2020
-
Reuters
How Pfizer vaccine could be cold comfort for some Asian nations
-
BioCentury
Reata, Calliditas make good on renewed interest in kidney disease with Phase III successes
-
CNN
Brazil suspends trials of China's Sinovac coronavirus vaccine, citing 'serious adverse event'
-
The Wall Street Journal
Biogen Stock Might Not Recover From Alzheimer's Treatment Setback
Nov 09, 2020
Nov 06, 2020
-
Reuters
Novo Nordisk to boost pill-form diabetic drugs with $1.8 billion deal
-
The New York Times
Opioid Epidemic Settlement Offer, Worth $26 Billion, Gains Support
-
Philadelphia Business Journal
Endo cutting 560 jobs over the next three years
-
Bloomberg
All-or-Nothing Bet on Bristol Drugs Goes Sour as FDA Reviews Lag
Previous
